Biostem Technologies, Inc. (OTC: BSEM) Announces the Appointment of Dr. Dave Woynarowski as Chief Medical Officer
February 01 2016 - 12:18PM
Marketwired
Biostem Technologies, Inc. (OTC: BSEM) Announces the Appointment
of Dr. Dave Woynarowski as Chief Medical Officer
OAKLAND PARK, FL-(Marketwired - Feb 1, 2016) - Dr. Dave
Woynarowski was appointed Chief Medical Officer of Biostem
Technologies, Inc. (OTC PINK: BSEM) effective immediately. Dr.
Woynarowski received his medical degree from Temple University, and
served as chief resident in his Internal Medicine Training program.
He went on to become part of the resident education system, and
twice receiving the prestigious Residents Teaching Award from his
students and residents. He holds a Master's Degree in Physiology,
and was a Certified Personal Trainer during his early medical
career. He also served as Adjunct Professor to Hershey School of
Medicine.
Dr. Woynarowski or more simply "Dr. Dave" as he is known to his
patients has a background in Internal Medicine, and has been board
certified in that discipline. He holds the A4M Anti-Aging medicine
certification and was one of the first 30 physicians in the world
to attain the AMA's certificate in Age Management Medicine. After
practicing Internal Medicine for 15 years and Anti-Aging Medicine
for 4 years he founded Dr. Dave's Best Nutraceuticals company in
2002 to fill the void in doctor designed nutraceuticals.
That company was acquired in November 2015 by Biostem
Technologies, Inc. and Dr. Dave continues to direct its main
functions including research and design.
Dr. Dave is also recognized as a worldwide expert on Telomeres
and Telomerase. He has lectured on the topic multiple times to such
groups as the A4M and AMMG.
In 2010 he wrote the first text book on Telomere biology for the
non-scientist with co authors Dr. Mike Fossel and Greta Blackburn.
Currently he is working on a second book which will include his
expertise on other age related topics including stem cells and gene
therapy.
On his transition to Biostem Technologies, Dr. Dave says, "This
is actually a manifestation of a long term dream of mine. I have
been working on developing a premier anti-aging team consisting of
scientists, researchers, and entrepreneurs who are as dedicated to
solving aging as I am. With that team now in place, I am excited to
begin pursuing ideas that have been on hold for so long. We look
forward to our ideas manifesting themselves into products and
services that will help more people sooner!"
About Biostem Technologies, Inc. (BSEM): Biostem Technologies
(BSEM) is engaged in the advancement of regenerative medicine and
anti-aging strategies throughout the United States, Europe, and
Latin America. BSEM's goal is to deliver the highest standard
wellness and stem cell products that are backed by science. Through
scientific studies, we seek to become a world leader in the
wellness arena. This will be accomplished by using the high quality
nutraceuticals and stem cells. Our quest is to introduce the world,
and our shareholders to our dedication to you and your
well-being.
Mission Statement- Biostem Technologies is a Global Leader in
Anti-Aging research. We are focused on advancing your quality of
life, health span, and wellness.
Vision Statement- Biostem Technologies is a group of scientists,
physicians, and visionaries creating the possibility of living life
to its fullest. Our products and strategies are dedicated to
helping you live your best, feel your best, and be your best.
Forward-Looking Statements Except for statements of historical
fact, the matters discussed in this press release are forward
looking and made pursuant to the Safe Harbor provisions of the
Private Securities Litigation Reform Act of 1995. "Forward-looking
statements" describe future expectations, plans, results, or
strategies and are generally preceded by words such as "future,"
"plan" or "planned," "expects," "believe" or "projected." These
forward-looking statements reflect numerous assumptions and involve
a variety of risks and uncertainties, many of which are beyond the
company's control that may cause actual results to differ
materially from stated expectations. These risk factors include,
among others, limited operating history, difficulty in developing,
exploiting and protecting proprietary technologies, intense
competition and additional risks factors as discussed in reports
filed by the company with OTC Markets.
Contact Information
- Contact: Biostem Technologies, Inc. Phone: 954-380-8342
Website: http://www.biostemtech.com Email: info@biostemtech.com
Twitter: @biostemtech Facebook: Biostem Technologies
BioStem Technologies (PK) (USOTC:BSEM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioStem Technologies (PK) (USOTC:BSEM)
Historical Stock Chart
From Apr 2023 to Apr 2024